Cell Signaling Technology, Inc. Announces Continued Collaboration with AstraZeneca PLC to Provide CST's PhosphoScan(R) Platform for Kinase Inhibitor Proteomic Profiling

DANVERS, Mass.--(BUSINESS WIRE)--Cell Signaling Technology, Inc. (CST) announced today a fourth agreement with AstraZeneca under which it will continue to perform CST’s PhosphoScan® technology to identify phosphorylation profiles and prospective biomarkers of kinase targeted lead compounds. CST’s PhosphoScan® proteomics technology is a patented methodology that enables the discovery of drug target phospho-profiles (PhosphoSignatures™) in cells and disease tissues. In the current research project, PhosphoScan® will be employed to validate phosphorylation site biomarkers on target kinases for antibody development, which is being pursued under a parallel research alliance between CST and AstraZeneca. PhosphoScan® proteomics is a well-utilized strategy for broad profiling of phosphorylation in cells and tissues. Quantification of compound-mediated changes in PhosphoSignatures™ may inform decisions about optimal phospho-epitope biomarkers of kinase target inhibition. PhosphoScan® profiling involves immunoaffinity purification and tandem mass spectroscopy and its effectiveness in kinase target and biomarker discovery in cancer was illustrated most recently in the journal Cell (Rikova K. et al, Cell 131, 1190-1203 (2007)).

Back to news